$MYL is still trading at less than 11 times 2013 projected earnings. I expect the multiple to increase to 14 - 16. That would give $MYL a stock price of $39.90 on the low end. It's also interesting that $MYL beat out much larger companies like Pfizer on their recent acquisition. The injectable market has a lot of opportunities for companies like $MYL as there are shortages in this space. I would think that this makes $MYL an attractive candidate for a larger drug company. It's also interesting that $MYL provided forecast on what they believe their earnings will be in 2018 which is more than double the projected earnings in 2013. With this kind of EPS growth in the next 5 years you would have to think that the multiple needs to come up from less than 11. So ask yourself do you think a PE of 11 is appropriate for this stock?
Everyone seems to just forget about the heavy debt load Mylan has. Further acquisitions will expand debt . Debt can only be repaid from profits. Current numbers in Yahoo indicate that the banks have $1.71 vs each $1.00 of shareholder equity. Guess who really controls Mylan.